Immix Biopharma Inc
Immix Biopharma Inc (IMMX) Covered Calls
As of September 25, 2026, IMMX has 16 covered call opportunities in the coming three months. Return ranges from 23.1 to 128.4% until expiration. Annualized return ranges from 56.3 to 725.7%. The nearest expiration is October 16, 2026. Maximum potential profit is $1,408.
Read more
Running IMMX covered calls helps you generate consistent income from Immix Biopharma Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Immix Biopharma Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best IMMX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if IMMX stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling IMMX covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Immix Biopharma Inc covered call is worth writing.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab.
The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Income-focused investors, long-term IMMX holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling IMMX covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Immix Biopharma Inc covered calls come to you, already filtered for the metrics that matter.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile61.11% Neutral
- Market cap (M$)785
- 52 weeks high-27.35%
- 52 weeks low451.26%
- Analyst recommendationStrong Buy
1.00 - Target price$23.86
91.82% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-06
- P/E—
- Future P/E—
- EPS (ttm)-0.88
- EPS growth next 5 years16.22%
As of September 25, 2026
| 2026-10-16 | 21 | 15.00 | 36.74 | 0.55 | 0.80 | 458.00 | 41.75 | 725.66 | -5.01 | +0.29 | 2,982 | 0.25 |
| 2026-11-20 | 56 | 17.50 | 59.53 | 0.50 | 1.85 | 703.00 | 64.08 | 417.69 | -4.56 | +0.34 | 557 | 1.35 |
| 2026-10-16 | 21 | 12.50 | 13.95 | 1.00 | 2.00 | 253.00 | 23.06 | 400.86 | -9.12 | +0.48 | 405 | 1.00 |
| 2027-02-19 | 147 | 22.50 | 105.10 | 0.05 | 2.25 | 1158.00 | 105.56 | 262.11 | -0.46 | +0.30 | 192 | 2.20 |
| 2026-11-20 | 56 | 15.00 | 36.74 | 0.05 | 2.90 | 408.00 | 37.19 | 242.41 | -0.46 | +0.42 | 71 | 2.85 |
| 2027-02-19 | 147 | 20.00 | 82.32 | 0.45 | 3.70 | 948.00 | 86.42 | 214.57 | -4.10 | +0.44 | 200 | 3.25 |
| 2027-05-21 | 238 | 25.00 | 127.89 | 0.05 | 4.80 | 1408.00 | 128.35 | 196.84 | -0.46 | +0.45 | 0 | 4.75 |
| 2026-11-20 | 56 | 12.50 | 13.95 | 1.50 | 2.30 | 303.00 | 27.62 | 180.03 | -13.67 | +0.52 | 220 | 0.80 |
| 2027-02-19 | 147 | 17.50 | 59.53 | 1.30 | 2.45 | 783.00 | 71.38 | 177.23 | -11.85 | +0.43 | 50 | 1.15 |
| 2027-05-21 | 238 | 22.50 | 105.10 | 0.05 | 4.80 | 1158.00 | 105.56 | 161.89 | -0.46 | +0.46 | 0 | 4.75 |
As of September 25, 2026
Sell covered calls with the data behind you
Find the best IMMX covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.
Start your 14-day free trial→